Browse
Search for other papers by Kristen R Lednovich in
Google Scholar
PubMed
Search for other papers by Sophie Gough in
Google Scholar
PubMed
Search for other papers by Medha Priyadarshini in
Google Scholar
PubMed
Search for other papers by Nupur Pandya in
Google Scholar
PubMed
Search for other papers by Chioma Nnyamah in
Google Scholar
PubMed
Search for other papers by Kai Xu in
Google Scholar
PubMed
Search for other papers by Barton Wicksteed in
Google Scholar
PubMed
Search for other papers by Sidharth Mishra in
Google Scholar
PubMed
Search for other papers by Shalini Jain in
Google Scholar
PubMed
Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA
Search for other papers by Joseph L Zapater in
Google Scholar
PubMed
Search for other papers by Jose Cordoba-Chacon in
Google Scholar
PubMed
Search for other papers by Hariom Yadav in
Google Scholar
PubMed
Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA
Search for other papers by Brian T Layden in
Google Scholar
PubMed
Short-chain fatty acids (SCFAs) are key nutrients that play a diverse set of roles in physiological function, including regulating metabolic homeostasis. Generated through the fermentation of dietary fibers in the distal colon by the gut microbiome, SCFAs and their effects are partially mediated by their cognate receptors, including free fatty acid receptor 2 (FFA2). FFA2 is highly expressed in the intestinal epithelial cells, where its putative functions are controversial, with numerous in vivo studies relying on global knockout mouse models to characterize intestine-specific roles of the receptor. Here, we used the Villin-Cre mouse line to generate a novel, intestine-specific knockout mouse model for FFA2 (Vil-FFA2) to investigate receptor function within the intestine. Because dietary changes are known to affect the composition of the gut microbiome, and can thereby alter SCFA production, we performed an obesogenic challenge on male Vil-FFA2 mice and their littermate controls (FFA2-floxed, FFA2fl/fl) to identify physiological changes on a high-fat, high-sugar ‘Western diet’ (WD) compared to a low-fat control diet (CD). We found that the WD-fed Vil-FFA2 mice were transiently protected from the obesogenic effects of the WD and had lower fat mass and improved glucose homeostasis compared to the WD-fed FFA2fl/fl control group during the first half of the study. Additionally, major differences in respiratory exchange ratio and energy expenditure were observed in the WD-fed Vil-FFA2 mice, and food intake was found to be significantly reduced at multiple points in the study. Taken together, this study uncovers a novel role of intestinal FFA2 in mediating the development of obesity.
Search for other papers by Thomas G Hill in
Google Scholar
PubMed
Search for other papers by Lorna I F Smith in
Google Scholar
PubMed
Search for other papers by Inmaculada Ruz-Maldonado in
Google Scholar
PubMed
Search for other papers by Peter M Jones in
Google Scholar
PubMed
Search for other papers by James E Bowe in
Google Scholar
PubMed
During pregnancy the maternal pancreatic islets of Langerhans undergo adaptive changes to compensate for gestational insulin resistance. The lactogenic hormones are well established to play a key role in regulating the islet adaptation to pregnancy, and one of the mechanisms through which they act is through upregulating β-cell serotonin production. During pregnancy islet serotonin levels are significantly elevated, where it is released from the β-cells to drive the adaptive response through paracrine and autocrine effects. We have previously shown that placental kisspeptin (KP) also plays a role in promoting the elevated insulin secretion and β-cell proliferation observed during pregnancy, although the precise mechanisms involved are unclear. In the present study we investigated the effects of KP on expression of pro-proliferative genes and serotonin biosynthesis within rodent islets. Whilst KP had limited effect on pro-proliferative gene expression at the time points tested, KP did significantly stimulate expression of the serotonin biosynthesis enzyme Tph-1. Furthermore, the islets of pregnant β-cell-specific GPR54 knockdown mice were found to contain significantly fewer serotonin-positive β-cells when compared to pregnant controls. Our previous studies suggested that reduced placental kisspeptin production, with consequent impaired kisspeptin-dependent β-cell compensation, may be a factor in the development of GDM in humans. These current data suggest that, similar to the lactogenic hormones, KP may also contribute to serotonin biosynthesis and subsequent islet signalling during pregnancy. Furthermore, upregulation of serotonin biosynthesis may represent a common mechanism through which multiple signals might influence the islet adaptation to pregnancy.
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Yizhou Zhang in
Google Scholar
PubMed
Search for other papers by Meiqin Chen in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Huan Chen in
Google Scholar
PubMed
Search for other papers by Shixiong Mi in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Chang Wang in
Google Scholar
PubMed
Search for other papers by Hongchun Zuo in
Google Scholar
PubMed
Search for other papers by Leigang Song in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Juan Du in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Huixian Cui in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Sha Li in
Google Scholar
PubMed
Aging-related reduction in androgen levels may be a possible risk factor for neurodegenerative diseases and contribute to cognitive impairment. Androgens may affect synaptic function and cognition in an androgen receptor (AR)-independent manner; however, the mechanisms connecting theses effects are unknown. Therefore, we used testicular feminization mutation (Tfm) male mice, a model with AR mutation, to test the effects of testosterone on synaptic function and cognition. Our results showed that testosterone ameliorated spatial memory deficit and neuronal damage, and increased dendritic spines density and postsynaptic density protein 95 (PSD95) and glutamate receptor 1 (GluA1) expression in the hippocampus of Tfm male mice. And these effects of testosterone were not inhibited by anastrozole, which suppressed conversion of testosterone to estradiol. Mechanistically, testosterone activated the extracellular signal-related kinase 1/2 (Erk1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) in the hippocampus of Tfm male mice. Meanwhile, Erk1/2 inhibitor SCH772984 blocked the upregulation of phospho-CREB, PSD95, and GluA1 induced by testosterone in HT22 cells pretreated with flutamide, an androgen antagonist. Collectively, our data indicate that testosterone may ameliorate hippocampal synaptic damage and spatial memory deficit by activating the Erk1/2–CREB signaling pathway in an AR-independent manner.
Search for other papers by Colin Farquharson in
Google Scholar
PubMed
Search for other papers by Ruth Andrew in
Google Scholar
PubMed
Department of Child Health, University of Arizona College of Medicine, Phoenix, Arizona, USA
Search for other papers by J Bryce Ortiz in
Google Scholar
PubMed
Search for other papers by Sebastian Tellez in
Google Scholar
PubMed
Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom
Search for other papers by Giri Rampal in
Google Scholar
PubMed
Search for other papers by Grant S Mannino in
Google Scholar
PubMed
Search for other papers by Nicole Couillard in
Google Scholar
PubMed
Search for other papers by Matias Mendez in
Google Scholar
PubMed
Search for other papers by Tabitha R F Green in
Google Scholar
PubMed
Search for other papers by Sean M Murphy in
Google Scholar
PubMed
Search for other papers by Rachel K Rowe in
Google Scholar
PubMed
Traumatic brain injury (TBI) can damage the hypothalamus and cause improper activation of the growth hormone (GH) axis, leading to growth hormone deficiency (GHD). GHD is one of the most prevalent endocrinopathies following TBI in adults; however, the extent to which GHD affects juveniles remains understudied. We used postnatal day 17 rats (n = 83), which model the late infantile/toddler period, and assessed body weights, GH levels, and number of hypothalamic somatostatin neurons at acute (1, 7 days post injury (DPI)) and chronic (18, 25, 43 DPI) time points. We hypothesized that diffuse TBI would alter circulating GH levels because of damage to the hypothalamus, specifically somatostatin neurons. Data were analyzed with generalized linear and mixed effects models with fixed effects interactions between the injury and time. Despite similar growth rates over time with age, TBI rats weighed less than shams at 18 DPI (postnatal day 35; P = 0.03, standardized effect size [d] = 1.24), which is around the onset of puberty. Compared to shams, GH levels were lower in the TBI group during the acute period (P = 0.196; d = 12.3) but higher in the TBI group during the chronic period (P = 0.10; d = 52.1). Although not statistically significant, TBI-induced differences in GH had large standardized effect sizes, indicating biological significance. The mean number of hypothalamic somatostatin neurons (an inhibitor of GH) positively predicted GH levels in the hypothalamus but did not predict GH levels in the somatosensory cortex. Understanding TBI-induced alterations in the GH axis may identify therapeutic targets to improve the quality of life of pediatric survivors of TBI.
Search for other papers by Sebastian R Vanin in
Google Scholar
PubMed
Search for other papers by Kendrick Lee in
Google Scholar
PubMed
Search for other papers by Mina Nashed in
Google Scholar
PubMed
Search for other papers by Brennan Tse in
Google Scholar
PubMed
Search for other papers by Mohammed Sarikahya in
Google Scholar
PubMed
Search for other papers by Sukham Brar in
Google Scholar
PubMed
Search for other papers by Gregg Tomy in
Google Scholar
PubMed
Search for other papers by Amica-Mariae Lucas in
Google Scholar
PubMed
Search for other papers by Thane Tomy in
Google Scholar
PubMed
Search for other papers by Steven R Laviolette in
Google Scholar
PubMed
Search for other papers by Edith J Arany in
Google Scholar
PubMed
The Lawson Health Research Institute and the Children's Health Research Institute, London, Ontario, Canada
Search for other papers by Daniel B Hardy in
Google Scholar
PubMed
Reports in North America suggest that up to 20% of young women (18–24 years) use cannabis during pregnancy. This is concerning given clinical studies indicate that maternal cannabis use is associated with fetal growth restriction and dysglycemia in the offspring. Preclinical studies demonstrated that prenatal exposure to Δ9-tetrahydrocannabinol, the main psychoactive component of cannabis, in rat dams led to female-specific deficits in β-cell mass and glucose intolerance/insulin resistance. Yet to date, the contributions of cannabidiol (CBD), the primary nonpsychoactive compound in cannabis, remain elusive. This study aimed to define the effects of in utero cannabidiol (CBD) exposure on postnatal glucose regulation. Pregnant Wistar rat dams received daily intraperitoneal injections of either a vehicle solution or 3 mg/kg of CBD from gestational day (GD) 6 to parturition. CBD exposure did not lead to observable changes in maternal or neonatal outcomes; however, by 3 months of age male CBD-exposed offspring exhibited glucose intolerance despite no changes in pancreatic β/α-cell mass. Transcriptomic analysis on the livers of these CBD-exposed males revealed altered gene expression of circadian rhythm clock machinery, which is linked to systemic glucose intolerance. Furthermore, alterations in hepatic developmental and metabolic processes were also observed, suggesting gestational CBD exposure has a long-lasting detrimental effect on liver health throughout life. Collectively, these results indicate that exposure to CBD alone in pregnancy may be detrimental to the metabolic health of the offspring later in life.
Search for other papers by Seokwon Jo in
Google Scholar
PubMed
Search for other papers by Emilyn U Alejandro in
Google Scholar
PubMed
The metabolic health trajectory of an individual is shaped as early as prepregnancy, during pregnancy, and lactation period. Both maternal nutrition and metabolic health status are critical factors in the programming of offspring toward an increased propensity to developing type 2 diabetes in adulthood. Pancreatic beta-cells, part of the endocrine islets, which are nutrient-sensitive tissues important for glucose metabolism, are primed early in life (the first 1000 days in humans) with limited plasticity later in life. This suggests the high importance of the developmental window of programming in utero and early in life. This review will focus on how changes to the maternal milieu increase offspring’s susceptibility to diabetes through changes in pancreatic beta-cell mass and function and discuss potential mechanisms by which placental-driven nutrient availability, hormones, exosomes, and immune alterations that may impact beta-cell development in utero, thereby affecting susceptibility to type 2 diabetes in adulthood.
Search for other papers by Neil Tanday in
Google Scholar
PubMed
Search for other papers by Aimee Coulter-Parkhill in
Google Scholar
PubMed
Search for other papers by R Charlotte Moffett in
Google Scholar
PubMed
Search for other papers by Karthick Suruli in
Google Scholar
PubMed
Search for other papers by Vaibhav Dubey in
Google Scholar
PubMed
Search for other papers by Peter R Flatt in
Google Scholar
PubMed
Search for other papers by Nigel Irwin in
Google Scholar
PubMed
The present study examines differences in metabolic and pancreatic islet adaptative responses following streptozotocin (STZ) and hydrocortisone (HC) administration in male and female transgenic GluCreERT2/Rosa26-eYFP mice. Mice received five daily doses of STZ (50 mg/kg, i.p.) or 10 daily doses of HC (70 mg/kg, i.p.), with parameters assessed on day 11. STZ-induced hyperglycaemia was evident in both sexes, alongside impaired glucose tolerance and reduced insulin concentrations. HC also had similar metabolic effects in male and female mice resulting in classical increases of circulating insulin indicative of insulin resistance. Control male mice had larger pancreatic islets than females and displayed a greater reduction of islet and beta-cell area in response to STZ insult. In addition, female STZ mice had lower levels of beta-cell apoptosis than male counterparts. Following HC administration, female mouse islets contained a greater proportion of alpha cells when compared to males. All HC mice presented with relatively comparable increases in beta- and alpha-cell turnover rates, with female mice being slightly more susceptible to HC-induced beta-cell apoptosis. Interestingly, healthy control female mice had inherently increased alpha-to-beta-cell transdifferentiation rates, which was decreased by HC treatment. The number of glucagon-positive alpha cells altering their lineage to insulin-positive beta cells was increased in male, but not female, STZ mice. Taken together, although there was no obvious sex-specific alteration of metabolic profile in STZ or HC mice, subtle differences in pancreatic islet morphology emphasises the impact of sex hormones on islets and importance of taking care when interpreting observations between males and females.
Search for other papers by S Khan in
Google Scholar
PubMed
Centre for Discovery Brain Science, University of Edinburgh, Hugh Robson Building, Edinburgh, UK
Search for other papers by D E W Livingstone in
Google Scholar
PubMed
Search for other papers by A Zielinska in
Google Scholar
PubMed
Search for other papers by C L Doig in
Google Scholar
PubMed
Search for other papers by D F Cobice in
Google Scholar
PubMed
Search for other papers by C L Esteves in
Google Scholar
PubMed
Search for other papers by J T Y Man in
Google Scholar
PubMed
Search for other papers by N Z M Homer in
Google Scholar
PubMed
Search for other papers by J R Seckl in
Google Scholar
PubMed
Search for other papers by C L MacKay in
Google Scholar
PubMed
Search for other papers by S P Webster in
Google Scholar
PubMed
Search for other papers by G G Lavery in
Google Scholar
PubMed
Search for other papers by K E Chapman in
Google Scholar
PubMed
Clinical & Translational Research Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, UK
Search for other papers by B R Walker in
Google Scholar
PubMed
Mass Spectrometry Core Laboratory, Edinburgh Clinical Research Facility, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
Search for other papers by R Andrew in
Google Scholar
PubMed
11β-Hydroxysteroid dehydrogenase 1 (11βHSD1) is a drug target to attenuate adverse effects of chronic glucocorticoid excess. It catalyses intracellular regeneration of active glucocorticoids in tissues including brain, liver and adipose tissue (coupled to hexose-6-phosphate dehydrogenase, H6PDH). 11βHSD1 activity in individual tissues is thought to contribute significantly to glucocorticoid levels at those sites, but its local contribution vs glucocorticoid delivery via the circulation is unknown. Here, we hypothesised that hepatic 11βHSD1 would contribute significantly to the circulating pool. This was studied in mice with Cre-mediated disruption of Hsd11b1 in liver (Alac-Cre) vs adipose tissue (aP2-Cre) or whole-body disruption of H6pdh. Regeneration of [9,12,12-2H3]-cortisol (d3F) from [9,12,12-2H3]-cortisone (d3E), measuring 11βHSD1 reductase activity was assessed at steady state following infusion of [9,11,12,12-2H4]-cortisol (d4F) in male mice. Concentrations of steroids in plasma and amounts in liver, adipose tissue and brain were measured using mass spectrometry interfaced with matrix-assisted laser desorption ionisation or liquid chromatography. Amounts of d3F were higher in liver, compared with brain and adipose tissue. Rates of appearance of d3F were ~6-fold slower in H6pdh−/− mice, showing the importance for whole-body 11βHSD1 reductase activity. Disruption of liver 11βHSD1 reduced the amounts of d3F in liver (by ~36%), without changes elsewhere. In contrast disruption of 11βHSD1 in adipose tissue reduced rates of appearance of circulating d3F (by ~67%) and also reduced regenerated of d3F in liver and brain (both by ~30%). Thus, the contribution of hepatic 11βHSD1 to circulating glucocorticoid levels and amounts in other tissues is less than that of adipose tissue.
Gulbali Institute, Charles Sturt University, Wagga Wagga, NSW, Australia
Search for other papers by Elizabeth M Simpson in
Google Scholar
PubMed
Search for other papers by Iain J Clarke in
Google Scholar
PubMed
Search for other papers by Christopher J Scott in
Google Scholar
PubMed
Gulbali Institute, Charles Sturt University, Wagga Wagga, NSW, Australia
Search for other papers by Cyril P Stephen in
Google Scholar
PubMed
Search for other papers by Alexandra Rao in
Google Scholar
PubMed
Gulbali Institute, Charles Sturt University, Wagga Wagga, NSW, Australia
Search for other papers by Allan J Gunn in
Google Scholar
PubMed
Our previous studies showed that microinjection into the median eminence of the sheep of glucagon-like peptide- 1 (GLP-1) or its receptor agonist exendin-4 stimulates luteinising hormone (LH) secretion, but it is unknown whether the same effect may be obtained by systemic administration of the same. The present study measured the response in terms of plasma LH concentrations to intravenous (iv) infusion of exendin-4. A preliminary study showed that infusion of 2 mg exendin-4 into ewes produced a greater LH response in the follicular phase of the oestrous cycle than the luteal phase. Accordingly, the main study monitored plasma LH levels in response to either 0.5 mg or 2 mg exendin-4 or vehicle (normal saline) delivered by jugular infusion for 1 h in the follicular phase of the oestrous cycle. Blood samples were collected at 10 min intervals before, during and after infusion. Both doses of exendin-4 increased mean plasma LH concentrations and increased LH peripheral pulse amplitude. There was no effect on inter-pulse interval or timing of the preovulatory LH surge. These doses of exendin-4 did not alter plasma insulin or glucose concentrations. Quantitative PCR of the gastrointestinal tract samples from a population of ewes confirmed the expression of the preproglucagon gene (GCG). Expression increased aborally and was greatest in the rectum. It is concluded that endogenous GLP-1, most likely derived from the hindgut, may act systemically to stimulate LH secretion. The present data suggest that this effect may be obtained with levels of agonist that are lower than those functioning as an incretin.
